{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/neogen-neog/",
 "dataUrl": "https://clearank.com/stock/neogen-neog/data.json",
 "title": "Neogen (NEOG) Stock Forecast & Price Target (2026)",
 "description": "Neogen Corp. (NEOG) stock: Healthcare, Medical Devices. $2.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Neogen Corp. (NEOG)",
 "published": "2026-07-25T10:03:42+00:00",
 "modified": "2026-09-16T07:46:10.759+00:00",
 "generated": "2026-09-16T11:54:50.985Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "NEOG",
  "name": "Neogen Corp.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.neogen.com"
 },
 "quote": {
  "price": 12.25,
  "previousClose": 11.95,
  "change": 0.3,
  "changePercent": 2.51,
  "open": 11.95,
  "high": 12.37,
  "low": 11.85,
  "volume": 3282400,
  "averageVolume": 2499010,
  "marketCap": 2671798561,
  "fiftyTwoWeekHigh": 12.85,
  "fiftyTwoWeekLow": 4.9,
  "marketOpen": false,
  "asOf": "2026-09-16T07:46:10.000Z"
 },
 "statistics": {
  "pe": -306.25,
  "eps": -0.04,
  "dividendYield": 0,
  "beta": 1.762,
  "priceToSales": 2.994447,
  "priceToBook": 1.2429789,
  "revenueTtm": 870400000,
  "grossMargin": 0.47847314691522413,
  "returnOnEquity": -0.00379
 },
 "technicals": {
  "rsi": 68.94,
  "macd": 0.24,
  "sma50": 11.03,
  "sma200": 9.55,
  "rsiSignal": "Bullish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 75,
  "consensus": "Buy",
  "fairValue": 12.25,
  "analystTarget": 14,
  "analystCount": 4,
  "wallStreetConsensus": "Strong Buy",
  "generatedAt": "2026-09-16T07:46:10.000Z",
  "priceAtAnalysis": 12.25,
  "volatility": {
   "daily": 1.9,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 12.01,
  "aggressiveEntry": 12.25,
  "stopLoss": 11.16,
  "stopLossPercent": 7,
  "targets": [
   12.61,
   13.21,
   13.81
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 7.09,
    "base": 12.23,
    "upside90th": 21.08
   },
   {
    "year": 2028,
    "downside10th": 5.65,
    "base": 12.21,
    "upside90th": 26.37
   },
   {
    "year": 2029,
    "downside10th": 4.74,
    "base": 12.18,
    "upside90th": 31.3
   },
   {
    "year": 2030,
    "downside10th": 4.09,
    "base": 12.16,
    "upside90th": 36.16
   },
   {
    "year": 2031,
    "downside10th": 3.59,
    "base": 12.14,
    "upside90th": 41.05
   },
   {
    "year": 2032,
    "downside10th": 3.19,
    "base": 12.12,
    "upside90th": 46.03
   },
   {
    "year": 2033,
    "downside10th": 2.86,
    "base": 12.1,
    "upside90th": 51.13
   },
   {
    "year": 2034,
    "downside10th": 2.59,
    "base": 12.07,
    "upside90th": 56.38
   },
   {
    "year": 2035,
    "downside10th": 2.35,
    "base": 12.05,
    "upside90th": 61.79
   },
   {
    "year": 2036,
    "downside10th": 2.15,
    "base": 12.03,
    "upside90th": 67.38
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "NEOG Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$11.95",
    "Day Range": "$11.85 to $12.37",
    "Prev Close": "$11.95",
    "Volume": "3.28M",
    "52-Week Range": "$4.90 to $12.85",
    "Market Cap": "$2.67B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+2,612%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "financials",
   "title": "NEOG Financial Performance",
   "text": [
    "Analysis: In the last 2 quarters, NEOG beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "NEOG Analysis",
   "text": [
    "Volume has increased 31.3% above its average, signaling heightened investor interest in Neogen Corp. The stock is trading above its 50-day SMA of $11.03 and its 200-day SMA of $9.55, indicating a positive short-to-medium term trend. The Relative Strength Index (RSI) is at 68.94, classifying it as bullish momentum, suggesting continued upward pressure. Key support levels are around the 50-day SMA, while resistance may be found near recent highs. The MACD indicator is positive at 0.24, further supporting the bullish sentiment. The stock's current price action suggests a continuation of the upward trend, supported by strong volume and positive technical indicators.",
    "Insiders have made net purchases totaling $779.3K with no reported sales, indicating strong confidence in the company's future prospects and potential for stock appreciation.",
    "Piper Sandler upgraded Neogen Corp. to 'Overweight' on August 26, 2026, signaling positive sentiment from sell-side analysts and potentially attracting further investor interest.",
    "The stock is trading above its 50-day and 200-day moving averages ($11.03 and $9.55) with a bullish RSI, suggesting a favorable technical setup for potential price increases.",
    "Neogen Corp. continues to report negative profit margins and EPS, which could limit investor appetite and valuation multiples if not addressed.",
    "Despite beating EPS estimates, the stock has seen negative price reactions, indicating that market focus may be on broader profitability and revenue trends rather than short-term earnings surprises.",
    "Neogen Corp.'s base case scenario anticipates continued upward momentum, supported by strong insider selling and a median analyst price target of $14.00, suggesting a 14.3% upside from the current $12.25 price. The company's ability to leverage its market position in medical devices and diagnostics, coupled with a return to positive revenue growth and improved profitability, will be critical for achieving this target. Potential catalysts for upside include successful product launches or market share gains, which could accelerate revenue growth and improve margins. Conversely, a failure to translate sales into profitability, increased competition, or a broader market downturn could pressure the stock. The company's negative profit margin remains a key area to monitor for a sustained turnaround."
   ],
   "lists": {
    "ProTips": [
     "Insider buying activity, with $779.3K in purchases and no reported sales, signals strong conviction from management and warrants close observation.",
     "The stock is trading above key moving averages (50-day and 200-day SMA) with bullish RSI momentum, suggesting potential for further price appreciation.",
     "Focus on Neogen's ability to achieve sustainable profitability and reignite revenue growth, as these factors are critical for long-term value creation and may outweigh short-term EPS beats."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Insider Net Buying Activity",
     "text": "Insiders have made net purchases totaling $779.3K with no reported sales, indicating strong confidence in the company's future prospects and potential for stock appreciation.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bullish",
     "title": "Analyst Upgrade to Overweight",
     "text": "Piper Sandler upgraded Neogen Corp. to 'Overweight' on August 26, 2026, signaling positive sentiment from sell-side analysts and potentially attracting further investor interest.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Positive Technical Momentum",
     "text": "The stock is trading above its 50-day and 200-day moving averages ($11.03 and $9.55) with a bullish RSI, suggesting a favorable technical setup for potential price increases.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Negative Profitability and EPS",
     "text": "Neogen Corp. continues to report negative profit margins and EPS, which could limit investor appetite and valuation multiples if not addressed.",
     "source": "Company Financials"
    },
    {
     "type": "Neutral",
     "title": "Recent Earnings Beat with Negative Price Reaction",
     "text": "Despite beating EPS estimates, the stock has seen negative price reactions, indicating that market focus may be on broader profitability and revenue trends rather than short-term earnings surprises.",
     "source": "Earnings Reports"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Neogen Corp. presents a mixed fundamental picture with a price-to-sales ratio of 2.99, which is lower than the sector median of 3.7, indicating a potential valuation advantage. The company's profit margin is negative at -0.91%, and its return on equity is -0.38%, reflecting current profitability challenges. However, the company maintains a debt-to-equity ratio of 0.39, suggesting a manageable debt load. While revenue growth has been slightly negative at -0.1%, forward estimates suggest a return to positive growth, with next year's revenue projected to grow by 2.00%. The company's ability to translate its sales into profitability will be key to its long-term success.",
    "Neogen Corp. has demonstrated a pattern of beating earnings estimates in recent quarters. For the quarter ending March 2026, actual EPS was $0.13, surpassing the estimate of $0.11 by 18.18%, although the stock experienced a -4.42% price decline. Prior to that, the quarter ending March 2026 saw an even larger beat of 80% ($0.09 actual vs. $0.05 estimate), followed by a -6.18% stock price drop. Despite these positive earnings surprises, the stock price reactions have been negative, suggesting that market sentiment may be more focused on revenue growth and overall profitability rather than short-term EPS beats. Forward estimates indicate a return to positive revenue growth in the upcoming quarters.",
    "Neogen Corp. faces risks related to its current negative profitability, with a net profit margin of -0.91% and a negative EPS of -0.04. While revenue growth is expected to turn positive, the company must demonstrate a clear path to sustained profitability to justify its current valuation. Additionally, the recent negative stock price reactions following positive earnings surprises suggest that investor sentiment may be cautious, requiring a stronger catalyst to drive sustained upside."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "2.67B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-0.0400"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "12.85"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "4.90"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bullish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($11.03) above the 200-day SMA ($9.549), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bullish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "68.94"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.24"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "11.03"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "9.55"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.08",
    "Correlation with Nasdaq 100 (QQQ)": "+0.06",
    "Correlation with Bitcoin (BTC)": "+0.08",
    "Correlation with Gold (XAU)": "-0.04"
   }
  },
  {
   "id": "trade-plans",
   "title": "NEOG Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (68.9) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$12.61",
    "TARGET 2": "$13.21",
    "TARGET 3": "$13.81",
    "STOP LOSS": "$11.16"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+5.31%",
    "Average Feb return": "-1.49%",
    "Average Mar return": "-2.93%",
    "Average Apr return": "-5.86%",
    "Average May return": "+3.46%",
    "Average Jun return": "+4.31%",
    "Average Jul return": "+4.39%",
    "Average Aug return": "+3.85%",
    "Average Sep return": "-5.80%",
    "Average Oct return": "-5.41%",
    "Average Nov return": "+6.46%",
    "Average Dec return": "+2.51%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.90%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in NEOG in September 2016 would be worth about $5,610 today, compared with about $35,497 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NEOG today could grow to about $9,822 by 2036 in the base case, with a bull case near $55,006 and a bear case around $1,754. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "NEOG Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $12.16 for NEOG by 2030 in the base case, from $12.25 today (1.0x over 4 years). The downside path ends near $4.09. These are outcomes of a Monte Carlo simulation run on NEOG's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using NEOG's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "NEOG simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$7.09",
        "$12.23",
        "$21.08"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$5.65",
        "$12.21",
        "$26.37"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$4.74",
        "$12.18",
        "$31.30"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$4.09",
        "$12.16",
        "$36.16"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$3.59",
        "$12.14",
        "$41.05"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$3.19",
        "$12.12",
        "$46.03"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$2.86",
        "$12.10",
        "$51.13"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$2.59",
        "$12.07",
        "$56.38"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$2.35",
        "$12.05",
        "$61.79"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$2.15",
        "$12.03",
        "$67.38"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "TEM Tempus AI Inc NASDAQ $68.85 +10.67%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "CNC Centene Corp. NYSE $67.66 -2.52%",
     "url": "https://clearank.com/stock/centene-cnc/"
    },
    {
     "text": "A Agilent Technologies, Inc. NYSE $150.27 +2.36%",
     "url": "https://clearank.com/stock/agilent-technologies-a/"
    },
    {
     "text": "CI The Cigna Group NYSE $288.98 -0.37%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $209.36 +3.01%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "HUM Humana Inc. NYSE $396.62 -2.56%",
     "url": "https://clearank.com/stock/hum-stock-analysis/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $143.17 -1.16%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "DXCM DexCom Inc. NASDAQ $86.45 +2.09%",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "STZ vs TAP Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/stz-vs-tap/"
    },
    {
     "text": "SNPS vs CDNS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/snps-vs-cdns/"
    },
    {
     "text": "VTI vs SPY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vti-vs-spy/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "NEOG Insider Trading Analysis",
   "facts": {
    "Bought": "$779.3K",
    "Sold": "None",
    "Insiders": "20",
    "Avg Transaction": "$52.0K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in NEOG",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Feb 18, 2020",
       "cells": [
        "HERBERT JAMES L Director",
        "Sell",
        "89.5K",
        "$6.4M"
       ]
      },
      {
       "label": "Jul 18, 2019",
       "cells": [
        "HERBERT JAMES L Director",
        "Sell",
        "56.2K",
        "$3.7M"
       ]
      },
      {
       "label": "Mar 31, 2021",
       "cells": [
        "ADENT JOHN EDWARD Chief Executive Officer",
        "Sell",
        "40.5K",
        "$3.6M"
       ]
      },
      {
       "label": "Jan 31, 2019",
       "cells": [
        "HERBERT JAMES L Director",
        "Sell",
        "49.4K",
        "$2.9M"
       ]
      },
      {
       "label": "Mar 31, 2021",
       "cells": [
        "MORRICAL TERRI A Divisional Officer",
        "Sell",
        "31.4K",
        "$2.8M"
       ]
      },
      {
       "label": "Jan 16, 2020",
       "cells": [
        "MORRICAL TERRI A Officer",
        "Sell",
        "39.5K",
        "$2.8M"
       ]
      },
      {
       "label": "Nov 23, 2018",
       "cells": [
        "HERBERT JAMES L Officer and Director",
        "Sell",
        "44.8K",
        "$2.7M"
       ]
      },
      {
       "label": "Jan 22, 2019",
       "cells": [
        "HERBERT JAMES L Chairman of the Board",
        "Sell",
        "45.3K",
        "$2.7M"
       ]
      },
      {
       "label": "Jan 13, 2021",
       "cells": [
        "PAPESH G BRUCE Director",
        "Sell",
        "30.0K",
        "$2.5M"
       ]
      },
      {
       "label": "Apr 18, 2019",
       "cells": [
        "HERBERT JAMES L Director",
        "Sell",
        "41.0K",
        "$2.3M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Neogen+Corp.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Neogen's stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Neogen's stock price is projected to be $12.16 in 2030 under a base case scenario. The downside projection is $4.09, while the upside projection reaches $36.16. These figures represent statistical outcomes and are not guaranteed price targets."
  },
  {
   "question": "Is Neogen Corp. a buy right now?",
   "answer": "Neogen Corp. is currently rated a 'Buy' with a consensus score of 75. The stock exhibits bullish technical momentum and strong insider selling, with a median analyst price target of $14.00, suggesting a 14.3% upside from the current price of $12.25."
  },
  {
   "question": "What are the key risks for Neogen Corp. investors?",
   "answer": "The primary risks for Neogen Corp. include its current negative profitability, evidenced by a negative net profit margin and EPS, and the need to reignite revenue growth. Recent stock price reactions to earnings beats also suggest cautious investor sentiment."
  },
  {
   "question": "How does Neogen Corp. compare to its sector peers?",
   "answer": "Neogen's price-to-sales ratio of 2.99 is below the sector median of 3.7, indicating a potential valuation discount. However, its profit margin and revenue growth are currently lagging behind the sector averages."
  },
  {
   "question": "What is the latest analyst sentiment on Neogen Corp. stock?",
   "answer": "The latest Wall Street consensus for Neogen Corp. is 'Strong Buy', with 2 out of 4 analysts rating it as such. The median analyst price target is $14.00, implying a 14.3% upside potential from the current stock price."
  },
  {
   "question": "What are the recent earnings trends for Neogen Corp.?",
   "answer": "Neogen Corp. has consistently beaten EPS estimates in recent quarters, including an 18.18% surprise in the quarter to March 2026. Despite these beats, the stock has seen negative price reactions, indicating a focus on broader profitability and revenue trends."
  },
  {
   "question": "What is the outlook for Neogen Corp.'s revenue growth?",
   "answer": "While Neogen Corp. experienced a slight revenue contraction of -0.1% recently, forward estimates project a return to positive growth. Next quarter's revenue is expected to grow by 2.00% year-over-year, and current year revenue growth is estimated at 1.00%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$68.85",
    "change": "+10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$67.66",
    "change": "-2.52%",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "A",
    "name": "Agilent Technologies, Inc. NYSE",
    "price": "$150.27",
    "change": "+2.36%",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$288.98",
    "change": "-0.37%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$209.36",
    "change": "+3.01%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "HUM",
    "name": "Humana Inc. NYSE",
    "price": "$396.62",
    "change": "-2.56%",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$143.17",
    "change": "-1.16%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "DXCM",
    "name": "DexCom Inc. NASDAQ",
    "price": "$86.45",
    "change": "+2.09%",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "STZ vs TAP Comparison",
    "name": "",
    "url": "https://clearank.com/compare/stz-vs-tap/"
   },
   {
    "ticker": "SNPS vs CDNS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/snps-vs-cdns/"
   },
   {
    "ticker": "VTI vs SPY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vti-vs-spy/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "COIN",
    "text": "↓ 10.10%",
    "url": "https://clearank.com/stock/coinbase-coin/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "OFIX",
    "text": "Orthofix Medical",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "text": "QuidelOrtho Corporation",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   },
   {
    "ticker": "SYK",
    "text": "Stryker Corporation",
    "url": "https://clearank.com/stock/stryker-syk/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/NEOG-neogen-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/NEOG-neogen-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Neogen (NEOG) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/neogen-neog/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/neogen-neog/",
        "name": "Neogen Corporation (NEOG) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/neogen-neog/#webpage",
     "url": "https://clearank.com/stock/neogen-neog/",
     "name": "Neogen (NEOG) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-25T10:03:42+00:00",
     "dateModified": "2026-09-16T07:46:10+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/NEOG-neogen-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/neogen-neog/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/neogen-neog/#richSnippet",
     "headline": "Neogen (NEOG) Stock Forecast & Price Target (2026)",
     "name": "Neogen (NEOG) Stock Forecast & Price Target (2026)",
     "description": "Neogen Corp. (NEOG) stock: Healthcare, Medical Devices. $2.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-25T10:03:42+00:00",
     "dateModified": "2026-09-16T07:46:10+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Neogen Corp.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "NEOG"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries. Its Food Safety segment provides test kits, culture media, and related products used by food and feed producers, processors, laboratories, and regulato",
      "tickerSymbol": "NEOG",
      "sameAs": "https://www.neogen.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/neogen-neog/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/NEOG-neogen-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/neogen-neog/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Neogen's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Neogen's stock price is projected to be $12.16 in 2030 under a base case scenario. The downside projection is $4.09, while the upside projection reaches $36.16. These figures represent statistical outcomes and are not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Neogen Corp. a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Neogen Corp. is currently rated a 'Buy' with a consensus score of 75. The stock exhibits bullish technical momentum and strong insider buying, with a median analyst price target of $14.00, suggesting a 14.3% upside from the current price of $12.25."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks for Neogen Corp. investors?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Neogen Corp. include its current negative profitability, evidenced by a negative net profit margin and EPS, and the need to reignite revenue growth. Recent stock price reactions to earnings beats also suggest cautious investor sentiment."
     }
    },
    {
     "@type": "Question",
     "name": "How does Neogen Corp. compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Neogen's price-to-sales ratio of 2.99 is below the sector median of 3.7, indicating a potential valuation discount. However, its profit margin and revenue growth are currently lagging behind the sector averages."
     }
    },
    {
     "@type": "Question",
     "name": "What is the latest analyst sentiment on Neogen Corp. stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The latest Wall Street consensus for Neogen Corp. is 'Strong Buy', with 2 out of 4 analysts rating it as such. The median analyst price target is $14.00, implying a 14.3% upside potential from the current stock price."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent earnings trends for Neogen Corp.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Neogen Corp. has consistently beaten EPS estimates in recent quarters, including an 18.18% surprise in the quarter to March 2026. Despite these beats, the stock has seen negative price reactions, indicating a focus on broader profitability and revenue trends."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Neogen Corp.'s revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "While Neogen Corp. experienced a slight revenue contraction of -0.1% recently, forward estimates project a return to positive growth. Next quarter's revenue is expected to grow by 2.00% year-over-year, and current year revenue growth is estimated at 1.00%."
     }
    }
   ]
  }
 ]
}